U.S. stocks lower as investors rotate out of tech ahead of Jackson Hole
Investing.com -- Danaher Corporation reported fourth quarter 2024 results that missed earnings estimates but beat on revenue, sending shares down 5% in early trading.
The life sciences and diagnostics company posted adjusted earnings per share of $2.14, falling short of analyst expectations of $2.15. Revenue came in at $6.54 billion, surpassing the consensus estimate of $6.39 billion and representing a 2% YoY increase. Non-GAAP core revenue grew 1% compared to the same quarter last year.
Despite the revenue beat, investors appeared focused on the earnings miss and cautious guidance. For the first quarter of 2025, Danaher (NYSE:DHR) expects non-GAAP core revenue to decline in the low-single digits YoY. However, the company projects full year 2025 non-GAAP core revenue to increase approximately 3% YoY.
"We finished the year strong, with better-than-anticipated core revenue in all three of our segments," said Rainer M. Blair, President and CEO. "Good execution by our team also drove solid cash flow and operating margin expansion."
For the full year 2024, Danaher reported revenues of $23.9 billion, flat compared to 2023, while non-GAAP core revenue decreased 1.5%. Operating cash flow was $6.7 billion and non-GAAP free cash flow reached $5.3 billion.